Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs First Solar, Inc. (FSLR) Price & Performance

Cassava Sciences IncTrade
First Solar, Inc.Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs First Solar, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while First Solar, Inc. trades at $178.43 (market cap $19.22B). The key difference: First Solar, Inc. is far larger — about 487.8× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 2,067,793). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and First Solar, Inc. for 76 Days on average.

FLNAFSLR
Market Cap
$39.40M$19.22B
Volume
759,0182,067,793
Sector
HealthEnergy
52-Week High
$4.64$318.30
52-Week Low
$0.68$172.11
Typical Hold Time
37 Days76 Days
Enterprise Value
-$43.28M$17.69B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.

The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.

First Solar, Inc.

First Solar (FSLR) trades at $178.36, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins expanding to 32.47%. Recent patent litigation against JA Solar and increased put option activity reflect mixed sentiment. Technical indicators show resistance at $182 and support at $175, with moving averages signaling bearish momentum.

FSLR presents a value opportunity with attractive valuation ratios (P/E 11.03, P/S 3.58) and analyst consensus price target of $267.59 (50% upside). Risks include sector-wide pressure from high borrowing costs and political uncertainty. Strong cash flow generation ($2.06B operating cash flow) and consistent earnings beats support long-term growth prospects despite near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNA
47% Buy53% Sell
Avg holding period · 37 Days
FSLR
100% Buy0% Sell
Avg holding period · 76 Days

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →

About First Solar, Inc.

First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.

Read more on FSLR →